(MENAFN- GlobeNewsWire - Nasdaq)
Pune, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The global acquired hemophilia treatment market is expected to reach ~US$ 17.15 billion by 2030 at a CAGR of 5.06% from 2022 to 2030, states Growth Plus Reports.
Acquired hemophilia is a genetic disease where the proteins that are responsible for coagulation of the blood are disabled which causes excessive bleeding. In acquired hemophilia, the patient's immune system attacks the blood-clotting protein that can lead to excessive blood loss. Hemophilia is further classified into type A, B, and C, the most commonly found type being hemophilia A in which factor VIII is affected.
Request a Sample Copy of the Research Report:
Report Scope & Segmentation:
| Report Coverage | Details |
| Market Size in 2021 | USD ~ 11 billion |
| Revenue forecast in 2030 | USD ~ 17.15 billion |
| Growth Rate | CAGR of ~5.06% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | Type, Therapy, Treatment, End-Use |
| Regional scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Market Drivers
The global acquired hemophilia treatment market is an emerging industry with steady overall growth. The continuous growth in acquired hemophilia incidences and upsurge in research and development (R&D) activities attribute to the growth of this market globally. Additionally, the rising awareness of acquired hemophilia among the general population with increasing government and private initiatives for facilitating hemophilia treatment helps to propel the market.
The global acquired hemophilia treatment market has been analyzed from five different perspectives – Type, Therapy, Treatment, End-User, and Region.
Excerpts from 'By Therapy Segmentation'
Based on therapy, the global acquired hemophilia treatment market has been segmented into:
- Gene Therapy
- Immune Tolerance Induction Therapy
- Replacement Therapy
- Others
Replacement therapy dominates this market with the largest revenue share in 2021. This therapy gives a better outcome for the patient; wherein the missing coagulation factor is replaced in patients. Additionally, gene therapy is the fastest growing segment in the global acquired hemophilia treatment market, owing to its increased access to recognizing defective DNA and advances in the field of gene therapy in restoring the defective with the functional one.
Excerpts from 'By Region Segmentation'
Geographically, the global acquired hemophilia treatment market is collective to:
- North America
- Europe
- Asia Pacific
- Rest of the World
North America dominates the global market with the largest revenue share. This is attributed to the vast patient base with the acquired hemophilia, higher healthcare expenditure, and greater awareness & initiatives in this region. Furthermore, growing government/private funding augmented the popularity and penetration of novel treatments. These are the few reasons that prove to be instrumental for the acquired hemophilia treatment market growth in North America. Europe market holds the second position in terms of revenue share. Rapid adoption of advanced technologies and growing government/private initiatives further boosts the market in Europe and thereby anticipate in overall market expansion.
Asia Pacific is the fastest-growing region in the global acquired hemophilia treatment market with significant development in the recent years. This growth can be attributed to increasing government/private initiatives, rising research and development (R&D) activities, growing public awareness, and rapid development in the healthcare infrastructure. Moreover, continuous growth in acquired hemophilia incidences further fuels the growth of the acquired hemophilia treatment market in Asia Pacific which in turn contributes to the market growth globally.
Browse the full report here:
Excerpts from 'Competitive Landscape'
Some of the prominent players operating in the global acquired hemophilia treatment market are:
- Pfizer Inc
- Genentech Inc
- CSL Ltd., Inc
- Biogen Idec, Inc
- Baxter International, Inc
- Hospira, Inc
- Novo Nordisk AS
- Biotest AG
- Octapharma AG and Spark Therapeutics Inc
- Among others
Table of Content:
INTRODUCTION Market Ecosystem Timeline Under Consideration Historical Years – 2020 Base Year – 2021 Forecasted Years – 2022 to 2030 Currency Used in the Report RESEARCH METHODOLOGY Research Approach Data Collection Methodology Data Sources Secondary Sources Primary Sources Market Estimation Approach Bottom Up Top Down Market Forecasting Model Limitations and Assumptions PREMIUM INSIGHTS Current Market Trend (COVID-19 Perspective) Key Players & Competitive Positioning (2021) MARKET DYNAMICS Drivers Restraints Opportunities
TOC Continued….
VALUE PROPOSITIONS RELATED TO THE REPORT :
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS :
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Request for customization of this research report at: VALUE PROPOSITIONS RELATED TO THE REPORT :
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS :
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Request for customization of this research report at:
About Us:
Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as 'Most Innovative Healthcare Market Research Company in 2020.
Tags Acquired Hemophilia Treatment
MENAFN05082022004107003653ID1104652442
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.